Croup v.1.
1: ED Management
PHASE I (E.D.)
Executive Summary
Explanation of Evidence Ratings
Test Your Knowledge
Summary of Version Changes
Inclusion Criteria
Pathophysiology
Previously healthy children
Age 6 months to 6 years
Not Recommended
Exclusion Criteria
Toxic appearance;
Symptoms suggestive of an alternative
diagnosis;
Known upper airway abnormality
Hypotonia or neuromuscular disorder
Signs of
impending
respiratory failure
Poor respiratory effort
Stridor may be present or
decreased
Listless or decreased LOC
Cyanosis / Hypoxemia
Cool
CoolMist
Mist
No evidence supporting the use of
cool mist for treatment of croup
Radiographs
No evidence that radiographs are
necessary in croup with typical
presentation that responds to therapy
Severity Assessment
Stridor at rest AND
one or more of the following:
No
Prominent sternal wall retractions
Tachypnea
Agitation / restlessness / tired appearing
Difficulty with talking or feeding
Evaluate
criteria for
racemic
epinephrine
If worsening or not meeting discharge
criteria consider racepinephrine
Admit if discharge criteria not met in
2 hours
Meets
discharge
criteria
Discharge criteria
not met within 2 hours
Yes
Racepinephrine 2.25% inhalation
solution (0.5 mL nebulized)
diluted in 3 mL NS
Dosage of 0.6mg/kg Dexamethasone
Steroids are beneficial for all patients
with croup
Observation with Respiratory
Assessment Q1 hour
Repeat Dexamethasone
No evidence that repeat doses of
dexamethasone improve outcomes
Give Racemic Epinephrine
Give Dexamethasone
(if not previously given)
Discharge criteria
not met
Viral PCR
FA
No evidence that laboratory tests
improve croup care
AND
Give Dexamethasone
(if not previously given)
Dosage of 0.6mg/kg Dexamethasone
Assess immediate
clinical response
Severity Assessment
Stridor at rest
Prominent sternal wall retractions
Tachypnea
Agitation / restlessness / tired appearing
Difficulty with talking or feeding
To Inpatient Management
Observation for 2 hr with minimum
Q1 hour assessments
Consider
alternative
diagnosis or
ICU admission
Off
Pathway
Racepinephrine effect lasts only 2 hours
If patient worsens, consider repeat
racepinephrine and admission
Meets
discharge
criteria
!
Children who
do not respond to
racepinephrine may have
an alternative diagnosis.
Consider further workup
Discharge Criteria
Minimal stridor at rest (stridor with
activity to be expected)
Minimal retractions
Able to talk or feed without
difficulty
2 hours since racepinephrine
Not
improved
Improved
Admit Criteria
Patients with continued stridor at
rest AND any symptoms listed in
the severity assessment above
Patients receiving 2 doses of
racepinephrine
Patients not otherwise meeting
discharge criteria
!
Consider
BACTERIAL
TRACHEITIS
in children who
appear toxic, either
before or after racepinephrine
Discharge
Instructions
Return for
increased work
of breathing
For questions concerning this pathway,
contact:
[email protected] 2012, Seattle Childrens Hospital, all rights reserved, Medical Disclaimer
Last Updated: 05/31/2012
Valid until: 12/01/2014
Croup v.1.1: Inpatient Management
PHASE II (Inpatient)
Not Recommended
Cool
CoolMist
Mist
No evidence supporting the use of
cool mist for treatment of croup
Inclusion Criteria
Previously healthy children
Age 6 months to 6 years
!
Signs of
impending
respiratory failure
Poor respiratory effort
Stridor may be present or
decreased
Listless or decreased LOC
Cyanosis / Hypoxemia
Viral PCR
FA
No evidence that laboratory tests
improve croup care
Exclusion Criteria
Toxic appearance;
Symptoms suggestive of an alternative
diagnosis;
Known upper airway abnormality
Hypotonia or neuromuscular disorder
Radiographs
No evidence that radiographs are
necessary in croup with typical
presentation that responds to therapy
Repeat Dexamethasone
No evidence that repeat doses of
dexamethasone improve outcomes
Severity Assessment
Stridor at rest AND
one or more of the following:
Prominent sternal wall retractions
Tachypnea
Agitation / restlessness / tired appearing
Difficulty with talking or feeding
No
Yes
Give Racemic Epinephrine
Give Dexamethasone
(if not previously given)
Dosage of 0.6mg/kg Dexamethasone
Steroids are beneficial for all patients
with croup
Racepinephrine 2.25% inhalation
solution (0.5 mL nebulized)
diluted in 3 mL NS
racepinephrine Q2 hrs; more
Can give xxxxxxxxxxxxxxxxxxx
than 1 additional dose on medical unit
requires MD evaluation
Racepinephrine can be ordered by the
physician more frequently than Q2 hrs if
the patient is worsening and MD bedside
evaluation is in progress
Give Dexamethasone
(if not previously given)
Dosage of 0.6mg/kg Dexamethasone
Evaluate
criteria for
racemic
epinephrine
Observe
Consider
BACTERIAL
TRACHEITIS
in children who
appear toxic, either
before or after racepinephrine
Assess immediate
clinical response
Children who
do not respond to
racepinephrine may have
an alternative diagnosis.
Consider further workup
Severity Assessment
Stridor at rest
Prominent sternal wall retractions
Tachypnea
Agitation / restlessness / tired appearing
Difficulty with talking or feeding
Not
Improved
Improved
Clinical Assessment
Observation
RN assess symptoms Q2
hr until patient meets
discharge criteria
If patient worsens, consider
repeat racepinephrine
Observation
Improved
RN assess symptoms
Q1 hr x 2 using severity
assessment
Worsening
Notify MD
Can repeat racepinephrine x 1
Consider alternative diagnosis
Consider blood gas
Consider RRT / ICU evaluation
Meets
Discharge
Criteria
Discharge Criteria
Minimal stridor at rest (stridor with
activity to be expected)
Minimal retractions
Able to talk or feed without difficulty
2 hours since racepinephrine
No supplemental oxygen for more
than 12 hours
Discharge
Instructions
Return for
increased work
of breathing
Off
Pathway
To ED Management
For questions concerning this pathway,
contact: [email protected]
2012, Seattle Childrens Hospital, all rights reserved, Medical Disclaimer
Last Updated: 05/31/2012
Valid until: 12/01/2014
Exclusion Criteria
Toxic Appearance
Symptoms suggestive of an alternative diagnosis:
o
o
o
o
Expiratory wheeze
Drooling or difficulty swallowing
Prolonged or recurrent stridor
Poor response to treatment
Known upper airway abnormality
o Laryngomalacia
o Tracheomalacia
o History of vascular ring/sling or tracheoesophageal fistula
Hypotonia or neuromuscular disorder resulting in
hypotonia
o Trisomy 21
To ED Management
To Inpatient
Management
Background: Croup
Also known as laryngotracheobronchitis
Viral illness
Most common in late fall to early winter
Results in inflammation and swelling of the upper airway
Most commonly caused by Parainfluenza virus
Other causes include:
Respiratory syncytial virus
Influenza A and B
Mycoplasma Pneumoniae
Other respiratory viruses
Symptoms
Sudden onset of barky cough
Inspiratory stridor
Hoarse voice
Respiratory distress
Can be accompanied by fever
May be abrupt in onset or be preceded by mild URI
symptoms
Natural Course
Symptoms are usually worse at night
Usually resolve within 48 hours
Often followed by upper respiratory infection type
symptoms
To ED Management
To Inpatient
Management
Racemic Epinephrine: Cautions!
Most patients with croup
demonstrate rapid and significant
improvement of symptoms with
administration of racemic
epinephrine
Consider further workup and
removal from the croup clinical
pathway if your patient does not
show improvement with
administration to racemic
epinephrine
!
Children who do
not respond to
racepinephrine may
have an alternative diagnosis.
Consider further workup
Alternative Diagnoses: Other Causes of Stridor
Foreign body
Retropharyngeal abscess
Hereditary angioedema
Congenital abnormality
o Vascular ring or sling
o Laryngomalacia
To ED Management
To Inpatient
Management
To ED Management
To Inpatient
Management
Severity Assessment
Upon presentation patient should be assessed for:
Stridor at rest
Retractions
Tachypnea
Mental status
Ability to talk or feed
Severity Assessment: Rationale
There is no validated tool to assess croup severity in the
clinical (non-research) setting
To standardize care we need common language to
discuss the severity of symptoms among patients
Based on the Westley Croup Score (Westley 1978)
Severity Assessment: Rationale
Focuses on specific symptoms that indicate a need for
racemic epinephrine (moderate to severe symptoms):
Stridor at rest
AND
ONE OR MORE OF THE FOLLOWING:
Prominent sternal wall retractions
Tachypnea
Agitated / restless / tired
Difficulty with talking or feeding
To ED Management
To Inpatient
Management
Dexamethasone
Dexamethasone is recommended for ALL patients
presenting with croup symptoms
FINDINGS:
Glucocorticoids are associated with an improved croup score at 6 hours
(-1.2 points) and at 12 hours (-1.9 points); NNT for improvement = 5
Fewer return visits in patients treated with glucocorticoids compared to
placebo
Length of hospital/ED stay was significantly decreased
(mean decrease of 12 hours)
Use of epinephrine is decreased
[LOE: , (Russell, 2011)]
Dexamethasone Dosage
A dosage of 0.6 mg/kg of dexamethasone should be given
Maximum dose of 16mg
Round dose to nearest 2mg dosage
Rationale:
In the absence of further evidence, a single oral dose of
dexamethasone, probably 0.6mg/kg, should be preferred because of
its safety, efficacy and cost effectiveness.
Most of the studies that compared dexamethasone to placebo
used the dosage of 0.6mg/kg (12 of 31 trials; N=2032)
There are small studies showing similar therapeutic effect at
lower doses, more studies need to be done before changing the
dosing recommendation.
[LOE: , (Russell, 2011)]
To Pg 2
To ED Management
To Inpatient
Management
Glucocorticoid Choice
Comparisons between steroids:
Combination of dexamethasone + budesonide is no better than
dexamethasone or budesonide alone
No difference between PO and IM dexamethasone
Dexamethasone and prednisolone are equally effective at 6 and 12
hours, but readmission is more likely with prednisolone
[LOE: , (Russell, 2011)]
Back
To ED Management
To Inpatient
Management
Racemic Epinephrine (racepinephrine)
Racemic epinephrine works by causing mucosal
vasoconstriction and reduction of subglottic edema
Nebulized epinephrine is associated with clinically and statistically
significant transient reduction of symptoms of croup at 30 minutes posttreatment. (3 studies, 94 children)
Evidence does not favor racemic epinephrine or L-epinephrine, or
Intermittent Positive Pressure Breaths (IPPB) over simple nebulization.
Treatment effect disappears after two hours.
There is no evidence, on average, to suggest that there was an increase or
worsening of croup score, as compared to the pre-treatment or baseline in
the group treated with epinephrine.
[LOE: , (Bjornson, 2011)]
Racemic Epinephrine: Who should receive it?
Children with severe respiratory distress (indicated by marked sternal
wall indwelling and agitation) [LOE: E (Expert Opinion), (Toward
Optimized Practice, 2008)]
Children with severe or life threatening croup [LOE: E, (Mazza, 2008)]
Compared with placebo or no treatment nebulized adrenaline is more
effective in the short-term at reducing symptom severity at 10-30
minutes in children with moderate to severe croup. [LOE: ,
(Johnson, 2004)]
Moderate/Severe =
To Pg 2
To ED Management
To Inpatient
Management
Racemic Epinephrine Administration
Note that racemic epinephrine is ordered under the name:
racepinephrine
(racepinephrine 2.25% inhalation solution)
Back
To ED Management
To Inpatient
Management
Racemic Epinephrine: Inpatient Management
Racemic epinephrine can be
given every 2 hours to patients
who meet severity criteria
We recommend that patients be
re-evaluated by MD if requiring
more than one additional dose of
racemic epinephrine after
admission
Racemic epinephrine can be
given more frequently than Q 2
hours, but should be done
cautiously in conjunction with
ongoing MD evaluation
To ED Management
Give Racemic Epinephrine
Racepinephrine 2.25% inhalation
solution (0.5 mL nebulized)
diluted in 3 mL NS
Q2 hrs; more
Can give racepinephrine
xxxxxxxxxxxxxxxxxxx
than 1 additional dose on medical unit
requires MD evaluation
Racepinephrine can be ordered by the
physician more frequently than Q2 hrs if
the patient is worsening and MD bedside
evaluation is in progress
Give Dexamethasone
(if not previously given )
Dosage of 0.6mg/kg Dexamethasone
To Inpatient
Management
Racemic Epinephrine:
Observation in the Emergency Department
Treatment effect disappears after two hours.
There is no evidence, on average, to suggest that there was an
increase or worsening of croup score, as compared to the pretreatment or baseline in the group treated with epinephrine. [LOE:
, (Bjornson, 2011)]
To ED Management
To Inpatient
Management
Other Cautions: Respiratory Failure!
One in 4,500 children (1 in 170 hospitalized
children) with croup are intubated
[LOE: E (Expert Opinion), (Toward
Optimized Practice, 2008)]
Hypoxemia is uncommon in otherwise
healthy children with croup and should be
viewed as a warning sign of possible
respiratory failure
To ED Management
!
Signs of
impending
respiratory failure
Poor respiratory effort
Stridor may be present or
decreased
Listless or decreased LOC
Cyanosis / Hypoxemia
To Inpatient
Management
To ED Management
To Inpatient
Management
To ED Management
To Inpatient
Management
To ED Management
To Inpatient
Management
Discharge Criteria: Emergency Department
Study of children (n=527) admitted to hospital with stridor and/or sternal
retractions at rest showed that only 1% of those who had resting stridor but no
sternal retractions (N=305) had worsening respiratory distress after admission.
(Wagner 1986)
A child with croup who received adrenaline and steroids may be discharged
after 3 hours observation if they are free of stridor and intercostal retractions at
rest and are clinically well. [LOE: E, (Mazza, 2008)]
Criteria for ED discharge:
Presence of mild symptoms either on initial evaluation or after a period of
observation
Children should not be discharged earlier than 2 hours after the
administration of adrenaline
Parents should be able to return for care if symptoms worsen [LOE: E
(Expert Opinion), (Toward Optimized Practice, 2008)]
To ED Management
To Inpatient
Management
Admission Criteria
There is evidence that
healthy children with mild
croup do not need admission
to the hospital
There is no evidence that
stratifies the risks/benefits of
whom to admit in the
moderate category
There is consensus that
patients with severe croup
should be admitted
To ED Management
To Inpatient
Management
Re-evaluation and Readiness for Discharge
Severity Assessment
Stridor at rest AND
one or more of the following :
Prominent sternal wall retractions
Tachypnea
Agitation / restlessness / tired appearing
Difficulty with talking or feeding
RN will assess severity symptoms
upon transfer to the medical unit
No
Yes
Give Racemic Epinephrine
Give Dexamethasone
(if not previously given )
Dosage of 0.6mg/kg Dexamethasone
Steroids are beneficial for all patients
with croup
If racemic epinephrine given,
observe patients hourly for 2 hours
Racepinephrine2.25% inhalation
solution (0.5 mL nebulized)
diluted in 3 mL NS
Can give racepinephrine
xxxxxxxxxxxxxxxxxxx
Q2 hrs; more
than 1 additional dose on medical unit
requires MD evaluation
Racepinephrine can be ordered by the
physician more frequently than Q2 hrs if
the patient is worsening and MD bedside
evaluation is in progress
Give Dexamethasone
(if not previously given )
Assess discharge readiness every 2
hours after arrival to floor
Dosage of 0.6mg/kg Dexamethasone
Observe
Assess immediate
clinical response
Severity Assessment
Patient can be discharged as soon
as discharge criteria are met
Stridor at rest
Prominent sternal wall retractions
Tachypnea
Agitation / restlessness / tired appearing
Difficulty with talking or feeding
Evaluate
criteria for
racemic
epinephrine
Improved
Observation
RN assess symptoms Q2
hr until patient meets
discharge criteria
If patient worsens, consider
repeat racepinephrine
To ED Management
Observation
Improved
To Inpatient
Management
RN assess symptoms
Q1 hr x 2 using severity
assessment
Worsening
Discharge Instructions
For patients being discharged from the emergency room, discharge
instructions will be provided from FirstNET
Call your Primary Health-Care Provider or return to
the Emergency Department if your child:
Breathing becomes more difficult or does not improve
with moist are treatments and calming techniques as
listed above
Has stridor at rest when calm and is working hard to
breathe
Has trouble swallowing or is drooling a lot
Is not able to take liquids
Shows signs of dehydration:
dry mouth
Call 9-1-1 if your child:
no tears when crying
Is having a hard time breathing
urinates less than 3 times in 24 hours
Lips or face look blue
Is too fussy or cannot be calmed
Is too sleepy
Seems sicker
To ED Management
To Inpatient
Management
Executive Summary
To Pg 2
Return to Home
Executive Summary
To Pg 3
Return to Home
Executive Summary
Return to Home
Self-Assessment
Completion qualifies you for 1 hour of Category II CME credit. If you are taking this self-assessment as a
part of required departmental training at Seattle Childrens Hospital, you MUST logon to Learning Center.
1.
The croup pathway is designed for patients:
a.
6 months to 6 years old
b.
With croup that are otherwise healthy
c.
With an upper airway abnormality
d.
With hypotonia
e.
Both a and b
2.
Symptoms of croup usually include all of the following EXCEPT:
a.
Fever
b.
Wheezing
c.
Inspiratory stridor
d.
Respiratory distress
e.
Barky cough
3.
True or False: A patient presenting with high fever, toxic appearance, and drooling should be placed immediately on the
croup pathway.
4.
Which of the following patients with suspected croup should receive dexamethasone?
a.
A patient with inspiratory stridor audible with agitation
b.
A patient with a barky cough and no respiratory distress
c.
A patient with inspiratory stridor at rest, significant tachypnea, and retractions
d.
All of the above
5.
Which of the following patients with suspected croup should receive racemic epinephrine(racepinephrine)?
a.
A patient with inspiratory stridor at rest and significant retractions
b.
A patient with inspiratory stridor at rest, who has no other evidence of increased work of breathing
c.
A patient with inspiratory stridor at rest and agitation/restlessness
d.
Answers a and c
e.
Answers a, b, and c
6.
After giving a patient racemic epinephrine (racepinephrine) for croup the patient ______
a.
Should be reassessed in one hour
b.
Can be discharged home
c.
Needs to be observed for at least 4 hours
d.
Should be admitted to the hospital if they are in the emergency department
e.
None of the above
7.
True or False: Hypoxemia is a common presenting feature of croup?
8.
All patients with suspected croup should get:
a.
Cool mist treatment
b.
A viral FA
c.
Lateral neck soft tissue X-ray
d.
Chest X-ray
e.
None of the above
9.
True or false: A patient that is admitted and receives epinephrine on the inpatient unit needs a re-evaluation immediately after
the treatment and then Q1 hour x2.
10.
The discharge criteria include all of the following EXCEPT:
a.
No stridor
b.
Minimal retractions
c.
Able to talk or feed without difficulty
d.
2 hours since racepinephrine
e.
No supplemental oxygen for more than 12 hours
Return to Home
View Answers
Answer Key
ANSWER KEY
1. Answer: e. Inclusion criteria for the croup pathway are: age 6 mo to 6 years and previously
healthy. Exclusion criteria include patients with upper airway abnormalities, toxic appearance, symptoms
suggestive of an alternative diagnosis, hypotonia, and neuromuscular disorders.
2. Answer: b. Croup is generally characterized by barky cough, inspiratory stridor, hoarse voice, respiratory
distress, fever, uri symptoms. Wheezing is not a sign of croup and suggests an alternative diagnosis.
3. Answer: FALSE. These are symptoms of epiglottitis. A bacterial illness that can be life threatening and
requires prompt recognition and treatment. Patients with croup generally have low grade fevers, do not appear
toxic, and are not drooling.
4. Answer: d. All patients with croup should receive a dose of steroids.
5. Answer: d. The decision to give racemic epinephrine is based on a severity assessment that includes stridor
at rest and one or more of the following: prominent retractions, significant tachypnea, agitation/restlessness/tired
appearing, difficulty with talking or feeding. Inspiratory stridor at rest without other signs of significant respiratory
distress does not necessitate racemic epinephrine, observation is appropriate.
6. Answer: e. A patient receiving racemic epinephrine should be reassessed immediately after for response,
must be observed for at least 2 hours and thus can not be discharged home immediately. A patient receiving
racemic epinephrine does not necessarily need to be admitted.
7. Answer: False. Hypoxemia is VERY UNCOMMON croup and signifies impending respiratory failure or a
serious alternative diagnosis.
8. Answer: e. None of the above therapies are recommended for typical patients with croup meeting the
inclusion criteria for the croup pathway.
9. Answer: True. After two hours of Q1 reassessments the patient can go to Q2 assessments until meeting
discharge criteria. The patient can be discharged whenever discharge criteria are met.
10. Answer: a. Stridor with activity is to be expected in patients with croup. Patients with minimal stridor at rest
that has remained stable and who dont show other significant signs of respiratory distress can be discharged
home.
Return to Home
Evidence Ratings
We used the GRADE method of rating evidence quality. Evidence is first assessed as to
whether it is from randomized trial, or observational studies. The rating is then adjusted in
the following manner:
Quality ratings are downgraded if studies:
Have serious limitations
Have inconsistent results
If evidence does not directly address clinical questions
If estimates are imprecise OR
If it is felt that there is substantial publication bias
Quality ratings can be upgraded if it is felt that:
The effect size is large
If studies are designed in a way that confounding would likely underreport the magnitude
of the effect OR
If a dose-response gradient is evident
Quality of Evidence:
High quality
Moderate quality
Low quality
Very low quality
Expert Opinion (E)
Reference: Guyatt G et al. J Clin Epi 2011: 383-394
To Bibliography
Return to Home
Bibliography
Guidelines and Reviews
Croup.(2008). CKS (Formerly PRODIGY)
Diagnosis and management of croup.(2008). Toward Optimized Practice
Bjornson, C., Russell, K.F., Vandermeer, B., Durec, T. Klassen, T.P., & Johnson, D.W. (2011). Nebulized
epinephrine for croup in Children. Cochrane Database of Systemic Reviews, 2, 006619.
Bjornson, CL et al. Croup Lancet. 2008. 371(9609) 329-339.
Johnson, et al. Croup Clinical Evidence. 2004; 12 401-426.
Mazza, D., Wilkinson, F., Turner, T., Harris, C., & Health for Kids Guideline Development Group. (2008). Evidence
based guideline for the management of croup. Australian Family Physician, 37(6 Spec No), 14-20.
Moore M, Little P. (2006) Humidified Air Inhalation for Treatment of Croup. Cochrane Database of Systematic
Reviews.
Russell KF, Liang Y, OGorman K, Johnson DW, Klassen TP. (2011) Glucocorticoids for croup. Cochrane
Database of Systematic Reviews, 1, 001955.
Wagner et al (1986) Management of Children Hospitalized for laryngotracheobronchitis. Pediatric Pulmonology
2(3), 159-162.
Westley CR, Cotton EK, Brooks JG. Nebulized racemic epinephrine by IPPB for the treatment of croup: a double
blind study. American Journal of Diseases of Children. 1978; 132: 484-87.
Return to Home
Return to Home
Summary of Version Changes
Version 1 (12/19/2011): Go live
Version 1b (05/31/2012): Updated Viral FA to Viral PCR.
Correction to Alternative Diagnosis slide: upset changed to onset
Return to Home
Medical Disclaimer
Medicine is an ever-changing science. As new research and clinical experience
broaden our knowledge, changes in treatment and drug therapy are required.
The authors have checked with sources believed to be reliable in their efforts to
provide information that is complete and generally in accord with the standards
accepted at the time of publication.
However, in view of the possibility of human error or changes in medical sciences,
neither the authors nor Seattle Childrens Healthcare System nor any other party
who has been involved in the preparation or publication of this work warrants that
the information contained herein is in every respect accurate or complete, and
they are not responsible for any errors or omissions or for the results obtained
from the use of such information.
Readers should confirm the information contained herein with other sources and
are encouraged to consult with their health care provider before making any
health care decision.
Return to Home
